Spectral AI

Dallas, TX, United States All United States companies → — Founded 2009

Imaging AI Specialist Medical Device / Hardware Specialty-Focused AI

Dermatology General Surgery Plastic Surgery

Dermatology AI Radiology & Imaging AI

Public

Claim this company

Products

SPECTRALMD DEEPVIEW WOUND IMAGING SYSTEM

Spectral AI, Inc.

Dermatology AI

The Spectral AI DeepView Wound Imaging System uses multispectral imaging and proprietary AI algorithms to provide immediate, objective predictions of wound healing potential, aiding clinicians in faster, more accurate treatment decisions.

Contact for pricing

See all 1 product →

About Spectral AI

Spectral AI is an artificial intelligence company specializing in predictive medical diagnostics, particularly in wound care. Their flagship product, the DeepView System, utilizes proprietary AI algorithms and multispectral imaging to assess tissue and predict wound healing potential. This technology aims to provide clinicians with objective and immediate insights into a wound’s capacity to heal, distinguishing between fully damaged, partially damaged, and healthy tissue—information often invisible to the naked eye.

The company’s initial focus is on burn indications, supported by significant contracts with the Biomedical Advanced Research and Development Authority (BARDA). The DeepView System delivers a binary prediction on whether a wound will heal by a specified time, aiding in crucial treatment decisions and risk stratification. Spectral AI is also expanding its AI platform to include diabetic foot ulcers (DFU) and other clinical indications, aiming to improve diagnostic accuracy, patient outcomes, and reduce healthcare costs.

Focus Areas

Medical diagnostics Predictive AI Wound care Burn assessment Diabetic foot ulcer assessment Multispectral imaging AI algorithms

Business Intelligence

Technology

DeepView® System, AI-driven wound diagnostics platform, Multispectral Imaging (MSI), Proprietary AI algorithms, Deep learning, "Seeing the Unknown®"

What Physicians Need to Know

Medical Diagnostics & Predictive AI

Spectral AI specializes in 'Day One' healing predictions for wounds, offering immediate and objective assessments of healing potential. Their DeepView® System uses AI and multispectral imaging to provide insights not visible to the human eye, aiding in faster and more accurate treatment decisions.

Wound Care & Burn Assessment

The DeepView® System provides non-invasive, real-time burn wound evaluation, predicting whether a burn will heal on its own or require surgical intervention. In studies, Spectral AI's algorithms have outperformed physicians in identifying non-healing burn tissue, achieving significantly higher sensitivity.

Diabetic Foot Ulcer (DFU) Assessment

Spectral AI is developing AI technology for DFU assessment to objectively predict a wound's healing potential, addressing the current reliance on subjective assessments. This aims to reduce unnecessary amputations and improve patient outcomes.

Multispectral Imaging & AI Algorithms

Their core technology combines proprietary multispectral optics and sensors with advanced machine learning algorithms to capture and analyze injured tissue images. This allows for the extraction of intrinsic tissue properties and structures.

Key Differentiators

Spectral AI's DeepView® technology is a first-of-its-kind in predicting tissue healing potential, having received FDA Breakthrough Designation for burns. It offers objective, standardized insights to reduce variability in wound assessment, especially in the critical first 24-48 hours post-injury. The system is non-invasive and provides rapid results.

Technology Stack

The DeepView® System utilizes multispectral imaging and deep learning algorithms. It is a mobile, cart-based platform that captures a single image in 0.2 seconds, with immediate output. The AI is trained and tested against a proprietary database of over 340 billion clinically validated data points.

Physician Tip

For physicians, Spectral AI's DeepView® System offers a powerful tool for objective, real-time wound assessment, particularly for burns and diabetic foot ulcers. It can significantly improve the accuracy of 'Day One' healing predictions, enabling earlier and more targeted interventions. This can lead to reduced diagnostic uncertainty, fewer unnecessary procedures, and improved patient outcomes. When using the DeepView AI® System for burn wounds, ensure all dressings and topical agents are removed and follow standard wound cleansing protocols before imaging. Remember to use the AI output in conjunction with your clinical judgment and the patient's overall condition.

While specific integration partners are not detailed in the provided information, Spectral AI's DeepView® System is designed as a mobile technology platform for bedside diagnosis, suggesting a focus on ease of use within existing clinical workflows. Its role as a clinical decision support tool implies potential for integration with electronic health records (EHR) systems to streamline data flow and treatment planning, though this is not explicitly stated. The company is committed to expanding its clinical applications for DeepView®, leveraging its AI data pipeline infrastructure, which may lead to further integration opportunities in the future.

Products by Spectral AI

1 product in the directory

SPECTRALMD DEEPVIEW WOUND IMAGING SYSTEM

Spectral AI, Inc.

Dermatology AI

Contact for pricing

What the Web Says

Spectral AI is a company focused on AI-driven medical diagnostics, particularly with their DeepView Wound Imaging System, which uses multispectral imaging and AI to predict wound healing potential. The company has received FDA approval for its DeepView AI Automated Wound Imaging System and is actively pursuing further indications beyond burns, such as diabetic foot ulcers. While there's enthusiasm for their innovative product and market potential, employer reviews indicate some concerns about company culture and management practices.

Overall: Mixed

Strengths

Innovative AI-driven diagnostic technology for wound care.
DeepView System provides objective and immediate assessment of wound healing potential.
Strong potential to disrupt and create a new diagnostic market in wound care.
Experienced management team and existing hospital partnerships.
DeepView AI System has achieved FDA approval.
High accuracy in burn tissue assessments, outperforming physicians.

Limitations

Limited public reviews available on major platforms like G2, Glassdoor, and Capterra specifically for Spectral AI's products or as an employer.
Employer reviews on Indeed mention concerns about company culture, long working hours, and management.
Some employees report a decline in culture and pressure for extra work.
Pay is perceived as low by some employees.

Based on reviews from: Elion Health, Reddit, MedTech Dive, Indeed.com, Investing.com, PitchBook, YouTube, Spectral AI Website

Last updated: 2026-10-20

Videos

News, demos, and interviews about Spectral AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Spectral AI →

View all on YouTube

Press & Coverage

Spectral AI, Inc. (Press Release)

Spectral AI's DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly

Spectral AI showcased its FDA-cleared DeepView™ System for Burn Indication at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly, highlighting its potential to aid emergency departments in burn care. The event provided a valuable opportunity to engage with emergency department decision-makers and discuss wound care assessment challenges.

2026-10

Spectral AI, Inc. (Press Release)

Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System

Spectral AI submitted a New Technology Add-On Payment (NTAP) application to the Centers for Medicare & Medicaid Services (CMS) for its DeepView™ System, aiming to secure additional hospital inpatient payment for eligible procedures. This application utilizes an alternative pathway and seeks to support hospitals in incorporating the DeepView System into clinical workflows.

2026-10

Spectral AI, Inc. (Press Release)

Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet

Spectral AI announced the completion of the first site initiation visit for a clinical study expanding the DeepView System's label to include burns of the head, hands, and feet. This initiative aims to broaden the application of their AI-driven medical diagnostics technology in wound care.

2026-10

Spectral AI, Inc. (Press Release)

Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication

Spectral AI announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System, authorizing commercial distribution in the United States for burn care. This classification is a significant milestone, allowing the company to commence commercialization activities.

2026-05

Spectral AI, Inc. (Press Release)

Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System

Spectral AI was awarded $31.7 million in funding from BARDA (Biomedical Advanced Research and Development Authority) to accelerate the development of its DeepView® System. This funding will support additional features and potentially lead to the procurement of up to 30 DeepView devices for U.S. burn and trauma centers.

2026-03

Nasdaq

Spectral AI Raises up to $15 Million of Debt Financing and Strengthens Financial Position for U.S. Commercialization

Spectral AI secured up to $15 million in debt financing from Avenue Venture Opportunities Fund II, L.P., strengthening its financial position for U.S. commercialization of the AI-driven DeepView® System. This funding is intended to support the company's efforts to bring its burn healing prediction technology to market.

2025-03

MedTech Dive

Spectral AI algorithms beat physicians in burn tissue assessments

Spectral AI's DeepView System demonstrated superior performance to physicians in burn tissue assessments, with the AI-enabled system achieving 68.5% accuracy compared to 39.2% for physicians. The company plans to submit these study results to the FDA by mid-2025.

2025-03

Journal of Burn Care & Research

Clinical Investigation of a Rapid Non-invasive Multispectral Imaging Device Utilizing an Artificial Intelligence Algorithm for Improved Burn Assessment

This peer-reviewed article details a clinical investigation into Spectral AI's non-invasive multispectral imaging device, which uses an AI algorithm for improved burn assessment. The study aims to provide objective and immediate assessment of a burn wound's healing potential.

2023-04

Frequently Asked Questions

What specific medical diagnostic problems does Spectral AI's technology address, particularly in wound care and burn assessment?

Spectral AI's technology focuses on providing rapid and accurate diagnostic support for wound care, with a particular emphasis on burn depth assessment and the early identification of diabetic foot ulcers. Their AI-driven multispectral imaging aims to differentiate between viable and non-viable tissue, which is crucial for treatment planning and improving patient outcomes.

How does Spectral AI's predictive AI integrate with existing clinical workflows, and what kind of training or support is provided for healthcare professionals?

Spectral AI's predictive AI is designed to seamlessly integrate into current clinical workflows by providing objective, data-driven insights at the point of care. They offer comprehensive training programs and ongoing technical support to ensure healthcare professionals can effectively utilize their devices and interpret the AI-generated assessments.

What are the regulatory compliance statuses (e.g., FDA approval) of Spectral AI's products for medical diagnostics, and how do they ensure data privacy and security?

Spectral AI is actively pursuing regulatory approvals, such as FDA clearance, for its diagnostic devices to ensure they meet the highest standards for medical use. They prioritize data privacy and security through robust encryption protocols and adherence to healthcare data regulations like HIPAA, safeguarding patient information.

What is the pricing model for Spectral AI's multispectral imaging and AI algorithm solutions, and are there options for different scales of healthcare facilities?

Spectral AI offers flexible pricing models for its multispectral imaging and AI algorithm solutions, which can be tailored to accommodate various healthcare facility sizes and needs, from individual clinics to large hospital networks. Specific pricing details are typically discussed directly with interested institutions to provide customized solutions.

What evidence supports the accuracy and efficacy of Spectral AI's AI algorithms for burn and diabetic foot ulcer assessment compared to current standard diagnostic methods?

Spectral AI's AI algorithms are backed by clinical studies demonstrating their accuracy and efficacy in assessing burn depth and identifying diabetic foot ulcers, often outperforming traditional diagnostic methods. Their technology aims to reduce inter-observer variability and provide more objective, earlier insights for improved patient management.

What partnerships does Spectral AI have with other healthcare technology companies or research institutions, and how do these collaborations enhance their offerings?

Spectral AI actively collaborates with leading healthcare technology companies and research institutions to advance their diagnostic capabilities and expand their product offerings. These partnerships foster innovation, facilitate broader market adoption, and ensure their technology remains at the forefront of medical diagnostics.

What is the long-term vision for Spectral AI's technology in medical diagnostics, and what is the company's stability and growth outlook?

Spectral AI's long-term vision is to revolutionize medical diagnostics by providing AI-powered, non-invasive tools that significantly improve patient outcomes in wound care and beyond. The company demonstrates strong stability and a positive growth outlook, driven by ongoing innovation, strategic partnerships, and increasing market demand for advanced diagnostic solutions.

Related Companies

Suggest an Edit → | Report an issue